Neuromyelitis optica spectrum disorder therapy class competition matures
Eculizumab, ravulizumab, satralizumab, inebilizumab, and emerging mechanism programs define a competitive NMOSD prescribing landscape.
Neuromyelitis optica spectrum disorder was an off-label-immunosuppression category until 2019 when eculizumab, satralizumab, and inebilizumab gained NMOSD approvals. Ravulizumab adds a longer-interval complement inhibitor option, FcRn antagonist programs in NMOSD are in pivotal data, and additional mechanism programs are in late-stage trials. The diagnostic-pathway question (anti-AQP4 antibody status defines treatment selection) is the addressable-population enabler.
Continue reading
Full intelligence on PanaceaIntel
PatientSpotlight publishes the headline framing. The full brief, the editorial takeaway, and the source list sit on PanaceaIntel for entitled clients.
New to PanaceaIntel? Request access and the team will reply within one working day.